Your Health, We Care
Avatrombopag is the world's first oral thrombopoietin receptor agonist (TPO-RA) approved by the US Food and Drug Administration (FDA) for the treatment of chronic liver disease (CLD) associated thrombocytopenia.
Patients treated with Avatrombopag have shown a significant increase in platelet count in clinical trials, reducing the occurrence of bleeding events. This improvement in efficacy is of great significance for improving patients' quality of life and prognosis.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
